Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development

Afzal-Ur-Rahman R Mohammed, Vincent W. Bramwell, Daniel J. Kirby, Sarah E. McNeil, Yvonne Perrie

Research output: Contribution to journalArticle

Abstract

The combination of dimethyl dioctadecyl ammonium bromide (DDA) and the synthetic cord factor trehalose dibehenate (TDB) with Ag85B-ESAT-6 (H1 fusion protein) has been found to promote strong protective immune responses against Mycobacterium tuberculosis. The development of a vaccine formulation that is able to facilitate the requirements of sterility, stability and generation of a vaccine product with acceptable composition, shelf-life and safety profile may necessitate selected alterations in vaccine formulation. This study describes the implementation of a sterilisation protocol and the use of selected lyoprotective agents in order to fulfil these requirements. Concomitantly, close analysis of any alteration in physico-chemical characteristics and parameters of immunogenicity have been examined for this promising DDA liposome-based tuberculosis vaccine. The study addresses the extensive guidelines on parameters for non-clinical assessment, suitable for liposomal vaccines and other vaccine delivery systems issued by the World Health Organisation (WHO) and the European Medicines Agency (EMEA). Physical and chemical stability was observed following alteration in formulations to include novel cryoprotectants and radiation sterilisation. Immunogenicity was maintained following these alterations and even improved by modification with lysine as the cryoprotective agent for sterilised formulations. Taken together, these results outline the successful alteration to a liposomal vaccine, representing improved formulations by rational modification, whilst maintaining biological activity.
LanguageEnglish
Pages404-412
Number of pages9
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume76
Issue number3
Early online date25 Sep 2010
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Liposomes
Vaccines
Cord Factors
Cryoprotective Agents
Tuberculosis Vaccines
Trehalose
Mycobacterium tuberculosis
Infertility
Lysine
Guidelines
Radiation
Safety
Proteins
dimethyldioctadecylammonium

Keywords

  • acyltransferases
  • immunologic adjuvants
  • animals
  • bacterial antibodies
  • bacterial antigens
  • bacterial proteins
  • cations
  • preclinical drug evaluation
  • liposomes
  • mice
  • inbred BALB C mice
  • mycobacterium tuberculosis
  • tuberculosis vaccines

Cite this

@article{96632ddc135641e493a4eda5d46c758f,
title = "Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development",
abstract = "The combination of dimethyl dioctadecyl ammonium bromide (DDA) and the synthetic cord factor trehalose dibehenate (TDB) with Ag85B-ESAT-6 (H1 fusion protein) has been found to promote strong protective immune responses against Mycobacterium tuberculosis. The development of a vaccine formulation that is able to facilitate the requirements of sterility, stability and generation of a vaccine product with acceptable composition, shelf-life and safety profile may necessitate selected alterations in vaccine formulation. This study describes the implementation of a sterilisation protocol and the use of selected lyoprotective agents in order to fulfil these requirements. Concomitantly, close analysis of any alteration in physico-chemical characteristics and parameters of immunogenicity have been examined for this promising DDA liposome-based tuberculosis vaccine. The study addresses the extensive guidelines on parameters for non-clinical assessment, suitable for liposomal vaccines and other vaccine delivery systems issued by the World Health Organisation (WHO) and the European Medicines Agency (EMEA). Physical and chemical stability was observed following alteration in formulations to include novel cryoprotectants and radiation sterilisation. Immunogenicity was maintained following these alterations and even improved by modification with lysine as the cryoprotective agent for sterilised formulations. Taken together, these results outline the successful alteration to a liposomal vaccine, representing improved formulations by rational modification, whilst maintaining biological activity.",
keywords = "acyltransferases, immunologic adjuvants, animals, bacterial antibodies, bacterial antigens, bacterial proteins, cations, preclinical drug evaluation, liposomes, mice, inbred BALB C mice, mycobacterium tuberculosis, tuberculosis vaccines",
author = "{R Mohammed}, Afzal-Ur-Rahman and Bramwell, {Vincent W.} and Kirby, {Daniel J.} and McNeil, {Sarah E.} and Yvonne Perrie",
note = "Copyright {\circledC} 2010 Elsevier B.V. All rights reserved.",
year = "2010",
month = "11",
doi = "10.1016/j.ejpb.2010.09.008",
language = "English",
volume = "76",
pages = "404--412",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Increased potential of a cationic liposome-based delivery system

T2 - European Journal of Pharmaceutics and Biopharmaceutics

AU - R Mohammed, Afzal-Ur-Rahman

AU - Bramwell, Vincent W.

AU - Kirby, Daniel J.

AU - McNeil, Sarah E.

AU - Perrie, Yvonne

N1 - Copyright © 2010 Elsevier B.V. All rights reserved.

PY - 2010/11

Y1 - 2010/11

N2 - The combination of dimethyl dioctadecyl ammonium bromide (DDA) and the synthetic cord factor trehalose dibehenate (TDB) with Ag85B-ESAT-6 (H1 fusion protein) has been found to promote strong protective immune responses against Mycobacterium tuberculosis. The development of a vaccine formulation that is able to facilitate the requirements of sterility, stability and generation of a vaccine product with acceptable composition, shelf-life and safety profile may necessitate selected alterations in vaccine formulation. This study describes the implementation of a sterilisation protocol and the use of selected lyoprotective agents in order to fulfil these requirements. Concomitantly, close analysis of any alteration in physico-chemical characteristics and parameters of immunogenicity have been examined for this promising DDA liposome-based tuberculosis vaccine. The study addresses the extensive guidelines on parameters for non-clinical assessment, suitable for liposomal vaccines and other vaccine delivery systems issued by the World Health Organisation (WHO) and the European Medicines Agency (EMEA). Physical and chemical stability was observed following alteration in formulations to include novel cryoprotectants and radiation sterilisation. Immunogenicity was maintained following these alterations and even improved by modification with lysine as the cryoprotective agent for sterilised formulations. Taken together, these results outline the successful alteration to a liposomal vaccine, representing improved formulations by rational modification, whilst maintaining biological activity.

AB - The combination of dimethyl dioctadecyl ammonium bromide (DDA) and the synthetic cord factor trehalose dibehenate (TDB) with Ag85B-ESAT-6 (H1 fusion protein) has been found to promote strong protective immune responses against Mycobacterium tuberculosis. The development of a vaccine formulation that is able to facilitate the requirements of sterility, stability and generation of a vaccine product with acceptable composition, shelf-life and safety profile may necessitate selected alterations in vaccine formulation. This study describes the implementation of a sterilisation protocol and the use of selected lyoprotective agents in order to fulfil these requirements. Concomitantly, close analysis of any alteration in physico-chemical characteristics and parameters of immunogenicity have been examined for this promising DDA liposome-based tuberculosis vaccine. The study addresses the extensive guidelines on parameters for non-clinical assessment, suitable for liposomal vaccines and other vaccine delivery systems issued by the World Health Organisation (WHO) and the European Medicines Agency (EMEA). Physical and chemical stability was observed following alteration in formulations to include novel cryoprotectants and radiation sterilisation. Immunogenicity was maintained following these alterations and even improved by modification with lysine as the cryoprotective agent for sterilised formulations. Taken together, these results outline the successful alteration to a liposomal vaccine, representing improved formulations by rational modification, whilst maintaining biological activity.

KW - acyltransferases

KW - immunologic adjuvants

KW - animals

KW - bacterial antibodies

KW - bacterial antigens

KW - bacterial proteins

KW - cations

KW - preclinical drug evaluation

KW - liposomes

KW - mice

KW - inbred BALB C mice

KW - mycobacterium tuberculosis

KW - tuberculosis vaccines

UR - http://www.scopus.com/inward/record.url?scp=78549280470&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2010.09.008

DO - 10.1016/j.ejpb.2010.09.008

M3 - Article

VL - 76

SP - 404

EP - 412

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 3

ER -